Name | Bromfenac sodium |
Synonyms | Duract Unii-8ecv571Y37 Bromfenac sodium Bromfenac ophthalmic Bromfenac ophthalmic solution Bromfenac Sodium Sesquihydrate Bromfenac monosodium salt sesquihydrate [2-amino-3-(4-bromobenzoyl)phenyl]acetic acid Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate Sodium [2-amino-3-(4-bromobenzoyl)phenyl]acetate 2-Amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt Sodium 2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate sodium {2-amino-3-[(4-bromophenyl)carbonyl]phenyl}acetate hydrate |
CAS | 91714-93-1 120638-55-3 |
EINECS | 695-342-6 |
InChI | InChI=1/C15H12BrNO3.Na.H2O/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;;/h1-7H,8,17H2,(H,18,19);;1H2/q;+1;/p-1 |
Molecular Formula | C15H11BrNNaO3 |
Molar Mass | 356.15 |
Melting Point | 268-270°C (dec.) |
Boling Point | 562.2°C at 760 mmHg |
Flash Point | 293.8°C |
Vapor Presure | 1.77E-13mmHg at 25°C |
Storage Condition | Refrigerator |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vitro study | Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs. Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs. Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs. |
In vivo study | Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats. Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats. Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs. Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats. Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice. Animal Model: Male Sprague-Dawley rats (150-250 g) are injected carrageenan Dosage: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Administration: Rubbed onto the backs before 1-72 h of injected carrageenan Result: Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%. |